Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Total Non-Current Liabilities (2018 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Total Non-Current Liabilities over the past 13 years, most recently at $182.2 million for Q2 2025.

  • Quarterly results put Total Non-Current Liabilities at $182.2 million for Q2 2025, down 3.1% from a year ago — trailing twelve months through May 2025 was $182.2 million (down 3.1% YoY), and the annual figure for FY2025 was $182.2 million, down 3.1%.
  • Total Non-Current Liabilities for Q2 2025 was $182.2 million at Lifecore Biomedical, Inc. \De\, up from $166.4 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for LFCR hit a ceiling of $301.6 million in Q1 2021 and a floor of $153.6 million in Q2 2023.
  • Median Total Non-Current Liabilities over the past 5 years was $187.3 million (2022), compared with a mean of $203.7 million.
  • Biggest five-year swings in Total Non-Current Liabilities: tumbled 39.95% in 2022 and later rose 22.43% in 2024.
  • Lifecore Biomedical, Inc. \De\'s Total Non-Current Liabilities stood at $264.0 million in 2021, then dropped by 22.47% to $204.6 million in 2022, then decreased by 0.66% to $203.3 million in 2023, then fell by 15.23% to $172.3 million in 2024, then grew by 5.71% to $182.2 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $182.2 million (Q2 2025), $166.4 million (Q1 2025), and $172.3 million (Q4 2024) per Business Quant data.